Trastuzumab emtansine
- Generic Name
- Trastuzumab emtansine
- Brand Names
- Kadcyla
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1018448-65-1
- Unique Ingredient Identifier
- SE2KH7T06F
- Background
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine deriva...
- Indication
Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
- Associated Conditions
- HER2-Positive Early Stage Breast Cancer, HER2-positive, Metastatic Breast Cancer
- Associated Therapies
- -
A Study of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo As a Treatment for Participants with Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT04740918
- Locations
- 🇺🇸
Emad Ibrahim, Md, Inc, Redlands, California, United States
🇦🇺Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
🇦🇺Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 130
- Registration Number
- NCT04680442
- Locations
- 🇧🇷
Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda, São Paulo, Brazil
🇧🇷Irmandade Da Santa Casa De Misericórdia De Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 139
- Registration Number
- NCT04675827
- Locations
- 🇫🇷
Institut Curie - Paris, Paris, France
🇫🇷CH Perpignan, Perpignan, France
🇫🇷CHU Poitiers, Poitiers, France
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04632992
- Locations
- 🇺🇸
Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
🇺🇸Ascension St. John Hospital, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1600
- Registration Number
- NCT04622319
- Locations
- 🇺🇸
MedStar Franklin Square Cancer Center at Loch Raven Campus, Baltimore, Maryland, United States
🇺🇸Houston Methodist Sugarland, Sugar Land, Texas, United States
🇺🇸MultiCare Cancer Center Puyallup, Puyallup, Washington, United States
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 920
- Registration Number
- NCT04589845
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
🇺🇸Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT04439110
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT04419181
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.